Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD

NCT03903809 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Dialysis-Dependent Chronic Kidney Disease

Interventions

DRUG: Pegol-Sihematide
DRUG: ESPO

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.